The Hematology Podcast

Send us Fan MailLymphomas represent the most common group of haematological malignancies, encompassing a broad spectrum of biologically and clinically distinct entities. Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) together account for the majority of B-cell non-Hodgkin lymphomas encountered in clinical practice. The therapeutic landscape across all three entities has undergone a profound transformation in recent years, driven by advances in molecular classification, the emergence of CAR-T cell therapies, bispecific antibodies, and targeted agents, fundamentally challenging established treatment paradigms and raising new questions around sequencing, patient selection, and long-term outcomes.Our guest today is Professor Mats Jerkeman, senior consultant haematologist and professor at Lund University Hospital, Sweden, one of Scandinavia's leading experts in lymphoma. Professor Jerkeman has extensive clinical and research experience spanning the full spectrum of B-cell lymphomas, with a particular focus on translational research, novel immunotherapy approaches, and Nordic collaborative trials. He is an active contributor to the Nordic Lymphoma Group and has been instrumental in shaping lymphoma management guidelines at both national and international levels.MAT-SE-2600313 (ver.2) 05.2026

Send us Fan MailImmune thrombocytopenia, the ITP is increasingly recognized as a complex immune‑mediated disease rather than just a disorder of low platelets. This episode, explores new developments in ITP, focusing on the complex immune disorder as the underlying mechanism of ITP and how immunological mechanisms translate into the diverse clinical manifestations seen in clinical practice.Expert guests in this episode are:Henrik Frederiksen, is a Consultant Hematologist and Clinical Professor at Odense University Hospital and University of Southern Denmark. He is an expert in benign hematology, particularly immune thrombocytopenia (ITP), and autoimmune hemolytic anemia (AIHA), and is an active contributor to EHA guideline development.Rick Kapur, MD, PhD, MSc, is a research group leader at Sanquin Blood Supply Foundation, Department Research, Amsterdam, The Netherlands. His research focuses on pathophysiology of immune-mediated disorders of platelets (e.g. immune thrombocytopenia; ITP) and endothelium (e.g. Transfusion-related acute lung injury; TRALI).Sanquin is the national blood service for Netherlands, knowledge institute in the field of blood, and internationally renowned research institute in the fields of blood transfusion medicine and immunology. This knowledge is applied for development and production of a range of pharmaceutical and diagnostic services.MAT-BE-2600181 (ver.1) Feb 2026

Send us Fan MailGaucher disease is a rare lysosomal storage disorder that presents with varying prevalence and management approaches across Nordic countries. Despite geographical proximity, these countries show notable differences in disease presentation, diagnostic approaches, and patient care pathways. This episode explores these unique challenges and opportunities while identifying potential areas for collaborative improvement in patient care across Scandinavia. Tune in to discover how this rare condition shapes healthcare approaches in the Nordic region. Featured Experts:Professor Allan Lund: Board-certified specialist in paediatrics with expert training in rare paediatric metabolism. He currently works at Rigshospitalet in Copenhagen, Denmark where he is the leader of Center for Rare metabolic diseases for children and adults. He has spent several years researching, diagnosing, and treating patients with different rare metabolic disorders.Dr. Per Ole Iversen: Medical doctor, specialist in internal medicine and hematology, senior consultant at the Department of Hematology at Oslo University Hospital (OUS), and professor of clinical nutrition at the University of Oslo. He has a particular interest in Gaucher disease and treats the majority of Norwegian Gaucher patients Among the Nordic countries, Denmark stands out as the only nation without a current dedicated Gaucher Patient Advocacy Group (PAG). However, Danish Gaucher patients are represented through the national rare disease umbrella organization "Sjældne Diagnoser" (Rare Diseases Denmark). This organization serves as a collective voice for patients with rare conditions, including those affected by Gaucher disease. In contrast, the other Nordic countries - Sweden, Norway, Finland, and Iceland - each have their own dedicated Gaucher PAGs. These organizations specifically focus on supporting Gaucher patients and their families, raising awareness, and advocating for their needs within their respective healthcare systems.MAT-BE-2500772 (ver.1) Jul 2025

Send us Fan MailHematopoietic stem cell transplantation is a crucial part of the treatment of many hematological malignancies. One important effect is alteration of the immune system. To overcome this, vaccinations after hematopoietic stem cell transplantation are a vital part of post-transplant care. The timing, and effectiveness of vaccines in this setting remain complex, as immune reconstitution varies widely. In this episode, we will explore current strategies and emerging insights into how best to safeguard allogenic transplanted patients against infections.Our guest is Sigrun Einarsdottir, hematologist and researcher with a focus on immune responses in immunocompromised patients. She completed her hematology fellowship and PhD at Sahlgrenska University Hospital in Gothenburg, Sweden in 2022, with her thesis centered on vaccine responses post-transplant. Sigrun is now a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, she continues her work on infections and vaccine responses, particularly after CAR T-cell therapy. Today, she’ll share her expertise on optimizing vaccination strategies in this vulnerable group.MAT-BE-2501090 (ver.1) 09 2025

Send us Fan MailThe integration of artificial intelligence (AI) into routine clinical practice is poised to revolutionize the diagnosis and treatment of hematologic diseases. AI-based models are already capable of automatically identifying cell populations including malignant cells, and facilitating early disease detection and prognosis. However, the efficacy of these tools depends on their correct application and interpretation, and hematologists need a basic understanding of machine learning to use AI effectively. In order to exploit the full potential of AI in hematologic diagnostics and to achieve a comprehensive integration of AI-based systems in routine clinical settings, there are challenges and limitations to be solved, including i.e. standardization of the methods, regulatory guidelines and training related questions. In this episode, we will dive into the current status and future directions of using AI in hematology. Oscar Brück, MD, PhD, is guest. He leads the Hematoscope Lab at the Helsinki University Hospital Comprehensive Cancer Center & Center of Diagnostics and the University of Helsinki. His team combines high-resolution imaging, big data, and machine learning to revolutionize the diagnosis and monitoring of hematological diseases. With a multidisciplinary expertise and approach, the group aims to harness technology to tackle cancer heterogeneity.MAT-BE-2500595 (ver.1) 05 2025

Send us Fan MailImmune Thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count, which can lead to increased bleeding and bruising. In this episode, we will discuss the pathophysiology, clinical implications, and advancements in ITP.Our guest today, Professor Waleed Ghanima, is a renowned hematologist at Østfold Hospital and the University of Oslo in Norway. Prof. Ghanima has extensive experience in the field of hematology and has contributed significantly to research on ITP. Today, he will share his insights on ITP, its clinical management, and future directions in research and management.MAT-BE-2500387 03.2025

Send us Fan MailA new genomic definition of high-risk multiple myeloma (HR-MM) has been recently proposed by IMS/IMWG. The associated peer-reviewed publication is planned to be released in Spring 2025.Expert guest in this episode is Professor Monique Minnema, haematologist at the University Hospital in Utrecht in The Netherlands. She is an international expert with focus on diagnosis and treatment of malignant haematological diseases including Multiple Myeloma and Waldenström disease. She just recently accepted the vice-chair position of the HOVON Multiple Myeloma Working Group in the Netherlands.MAT-BE-2500276 2/2025

Send us Fan MailIn this episode of The Hematology Podcast, we will delve into the complex world of thrombotic microangiopathy, or TMA. This condition encompasses a group of disorders characterized by small blood clots forming in the smallest blood vessels, leading to various complications. Diagnosing TMA can be particularly challenging due to its overlapping symptoms with other conditions and the need for specialized tests.In today’s episode, we have the honor of welcoming Professor Riitta Lassila to the studio. Professor Lassila is a renowned expert in hematology with extensive experience in researching and treating TMA. She currently serves at the Helsinki University Hospital in Finland, where she leads the Hemostasis and Thrombosis Research Unit. Her groundbreaking work has significantly advanced our understanding of TMA and its management.MAT-BE-2401005 (ver. 1) 11 2024

Send us Fan MailIn this episode, we dive into the fascinating world of liquid biopsy-derived DNA as a revolutionary tool for comprehensive mutation profiling in multiple myeloma. This innovative approach offers a non-invasive way to analyse genetic alterations, potentially transforming how we diagnose and monitor this complex hematological cancer. Join us as we explore the promises and challenges of using liquid biopsies to decode the genetic landscape of multiple myeloma and its implications for personalized medicine.  We have the pleasure of welcoming Dr. Wouter De Brouwer from Belgium to our studio. Dr. De Brouwer is a haematologist in training and PhD student at the hematology and immunology research group (HEIM) from the faculty of Brussels health campus, with a special interest in genomic profiling in haematological malignancies. Join us as Dr. De Brouwer sheds light on the potential of liquid biopsies to revolutionize personalized medicine and improve patient outcomes. ASSET-24016322 (ver. 1.0) Oct 2024

Send us Fan MailIn this episode, we focus on Thalassemia major, a severe form of the disease. In a previous episode, we discussed Thalassemia minor and intermedia with Professor Dr. Bart Biemond from Amsterdam UMC. Now, we will delve deeper into the challenges and treatments associated with Thalassemia major. Prof. Biemond is still with us to share his expertise.Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations.  ASSET-24016319 (ver. 2.0) Oct 2024